Skip to main
EXAS
EXAS logo

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 58%
Buy 32%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences has experienced a notable growth trajectory with its Cologuard screening test, which reported a ~14% increase in volumes due to re-screening traction, care gap programs, and expanded ordering providers, contributing to an enhanced revenue guidance for FY'25. The company's strategic investment in sales and marketing, which grew over 20% year-over-year in Q1'25, underscores its commitment to accelerating the adoption of Cologuard Plus, further solidifying its market position. Additionally, the upcoming product launches and pipeline advancements, including the BLUE-C blood-based testing readout and the CancerGuard launch in H2'25, present significant catalysts that could drive future growth.

Bears say

Exact Sciences faces a negative outlook primarily due to concerns regarding its product launches and growth projections. With historical multiples of 11.3x for other diagnostic companies serving as a benchmark, any failure of Exact's products to gain traction could lead to significant reevaluation relative to low-growth peers. Additionally, the introduction of Oncodetect is not anticipated to positively impact the company’s financial guidance for FY'25 and is expected to hinder gross margins in the second half of that year, further exacerbating concerns over profitability.

Exact Sciences (EXAS) has been analyzed by 19 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 32% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 19 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.